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The Relationship Between Mental Health, Disease
Severity, and Genetic Risk for Depression in Early
Rheumatoid Arthritis
Jack Euesden, PhD, Faith Matcham, MSc, Matthew Hotopf, PhD, Sophia Steer, PhD,
Andrew P. Cope, PhD, Cathryn M. Lewis, PhD, and Ian C. Scott, PhD
ABSTRACT
Objective: Reduced mental health (MH) is prevalent in rheumatoid arthritis (RA). Although longitudinal studies are limited, there is ev-
idence that depression is associated with worse disease outcomes. We evaluated reciprocal relationships between MH, RA severity, and
genetic risks for depression for 2 years in a well-characterized cohort of RA patients.
Methods:We evaluated 520 early RA patients previously enrolled to two clinical trials. MH was measured using the short form-36 MH
domain and mental component summary scores (MCS). MCS/MH associations over 2 years with disease activity (disease activity score on
a 28-joint count), disability (health assessment questionnaire), pain visual analog scale scores, and a weighted genetic risk score for depres-
sion were tested using linear mixed-effects and regression models.
Results: PoorerMHwas associated with worse RA outcomes. LowerMCS scores (indicating worseMH)were seen in patients with a greater
genetic risk for depression (weighted genetic risk score: coefficient = −1.21, p = .013). Lower baselineMCSwas associated with lower 2-year
improvements in disease activity score on a 28-joint count (coefficient = −0.02, p < .001), pain (coefficient = −0.33, p < .001), and health
assessment questionnaire (coefficient = −0.01, p = .006). Baseline MCS was associated with changes in the swollen joint count (coeffi-
cient = −0.09, p < .001) and patient global assessment (coefficient = −0.28, p < .001) but not the tender joint count (p = .983) and erythrocyte
sedimentation rate (p = .973). Only baseline pain visual analog scale (coefficient = −0.07, p = .002) was associatedwith 2-year changes inMCS.
Conclusions: Reduced baseline MH was associated with lower improvements in disease activity, disability, and pain for 2 years,
supporting current national guidelines recommending screening for depression in RA. Pain had a bidirectional relationship with MH. De-
pression genetic risk had a significant association with MH.
Key words: disability, disease activity, genetics, mental health, pain, rheumatoid arthritis.
INTRODUCTION
Reduced mental health (MH) is prevalent in rheumatoid arthri-tis (RA), with major depression present in 16.8% of patients
(1). The cause of this excess burden of MH impairment is uncer-
tain. Comorbid depression also seems to have a detrimental impact
on the disease course of RA, being associated with increased
healthcare use and costs (2) and representing an independent risk
factor for nonsuicide-related mortality (3). Determining the cause
and effect of depression in RA is, therefore, a key research goal.
Research in this area has mainly involved cross-sectional stud-
ies in patients with long-standing RA. These identified associa-
tions between depression and pain (4), disability (5), and arthritis
disease activity (6). Their cross-sectional nature, however, made
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it impossible to infer causality. Although longitudinal studies are
limited, there is some evidence for a bidirectional effect with pain
in patients with musculoskeletal disorders, whereby depression in-
fluences pain and vice versa (7,8). There is also some evidence that
depression predicts the subsequent disease activity of RA, with an
analysis of established RA patients finding a slower rate of decline in
disease activity over time in patients with a history of depression (9).
Depression also has a substantial genetic component (10), with
several variants associated with depression identified in a genome-
wide association study (GWAS) (11). This is consistent with previ-
ous twin studies of the heritability of major depressive disorder
(MDD), which found that the disorder has a heritability of 48%
to 75%, depending on assumptions made on the prevalence of
MDD in the general population (12). The role of these in determin-
ing MH in RA has not previously been evaluated.
The aim of our study was to evaluate the relationship between
MH and disease activity, disability, pain, and genetic risk for de-
pression for 2 years in a well-characterized clinical trial cohort of
patients with early RA. The direction of any associations was
tested by examining the impact of baseline MH on changes in dis-
ease activity, disability and pain, and vice versa.
METHODS
Participants
We studied patients in the CombinationAnti-Rheumatic Drugs in Early RA
(CARDERA) genetics cohort. It has been described in detail previously
(13). In brief, it comprises European ancestry RA patients enrolled to
two multicenter randomized controlled trials (RCTs): CARDERA-1 and
CARDERA-2 (14,15). Both recruited patients with early RA (<2-year dura-
tion) and active disease defined as three of three or more swollen joints, six or
more tender joints, 45-minute or more morning stiffness, or erythrocyte sed-
imentation rate (ESR) of 28mm/h or greater. CARDERA-1 recruited patients
between 2000 and 2002; CARDERA-2 recruited patients between 2003 and
2010. CARDERA-1 randomized patients to receive either (1) methotrexate;
(2) methotrexate and ciclosporin; (3) methotrexate and prednisolone; or
(4) methotrexate, ciclosporin, and prednisolone. CARDERA-2 randomized
patients to receive either (1) methotrexate or (2) methotrexate and anakinra.
Because the original aim of the CARDERA studies was to investigate the
performance of combination therapy with reference to monotherapy, a pla-
cebo groupwas not assigned. Rheumatoid factor (RF), a biomarker providing
clinical information on the antibody composition of patient serum, was
assayed as described previously (16). Follow-up was 2 years. The current
analysis is restricted to the 520 patients with baseline MH data available.
Disease Outcomes
The following disease outcomes were captured. First, disease activity (how
active a patient's arthritis is) was recorded using the disease activity score
on a 28-joint count (DAS28). This composite score combines information
on the number of swollen and tender joints (assessed by a clinician from
28 joint counts), the patient global assessment (PGA) of disease activity
(which involves a patient rating his or her overall disease activity on a
100-mm visual analog scale [VAS]), and the ESR in a mathematical for-
mula to give an assessment of RA activity ranging from 0 to 10. Lower
scores indicate less active disease, with scores of higher than 5.1, lower
than 3.2, and lower than 2.6 indicating high disease activity, low disease ac-
tivity, and remission, respectively. Second, disability was recorded using
the health assessment questionnaire (HAQ), a patient-completed question-
naire giving a score of function ranging from 0 to 3. HAQ scores of lower
than 1, 1 to 2, and higher than 2 indicate mild, moderate, and severe disabil-
ity, respectively. Third, pain was recorded using a 100-mm patient com-
pleted pain VAS, a method for quantifying the severity of self-reported
pain (17). Fourth, health-related quality of life (HRQoL) was recorded
using the short form-36 (SF-36), which is described in detail hereinafter.
InCARDERA-1, the aforementioned outcomeswere captured every 6months.
In CARDERA-2, they were captured at 0, 6, 12, and 24 months.
Mental Health
The SF-36 is a generic measure of health status, capturing HRQoL across
eight domains (4 physical and 4 mental) (18). These domains are scored
from 0 to 100, with higher scores indicating better HRQoL. They can be
normalized, z-transformed, and combined into mental component summary
(MCS) and physical component summary scores providing summary mea-
sures of overall mental and physical health, relative to a population mean
score of 50 (SD = 10) (19).
We used the MH domain score and MCS as measures of MH in our
analysis. Both have been used to screen for depression, with anMCS cutoff
of 42 having a sensitivity and specificity of 74% and 81%, respectively, for
detecting depressive disorder (20). They also associate with depression se-
verity, both cross-sectionally and over time (21).
Genotyping
CARDERA patients were genotyped on the Illumina ImmunoChip array
(described in detail previously (13)). Single nucleotide polymorphism
(SNP)markers were removed that hadmore than 5%missingness, were du-
plicates, were not in Hardy-Weinberg equilibrium (HWE, p < .00001), and
had a minor allele frequency (MAF) of less than 0.01. From 196,524 pre–
quality control markers, 138,873 were available in the final data set. Impu-
tation was subsequently performed using IMPUTE2 (22) and the 1000
Genomes Phase 1 integrated variant version 3 (March 2012) reference panel
(variants filtered with a European MAF <0.01). Postimputation SNPs were
removed with low INFO scores (<0.7), MAF (<0.05), HWE (p < .000001),
and genotyping rate (<0.1), resulting in 429,193 available markers.
Genetic Risk for Depression
The Psychiatric Genomics Consortium MDD GWAS mega-analysis failed
to find a locus of genome-wide significance, likely reflecting limited power
caused by the genetic architecture of MDD (small effect sizes of individual
genetic variants) and the high prevalence of MDD, which increases the dif-
ficulty in recruiting large samples of screened, low-risk controls (23). We
therefore tested a weighted genetic risk score (wGRS), combining loci of
nominal association withMDD for an association with MH in CARDERA.
This approach is commonly used in studies of polygenic disorders, whose
genetic architecture comprises thousands of very small effect common al-
leles (24,25). We used a p value threshold (pT) for SNPs to include in the
wGRS of 0.05 (representing nominal association with MDD). A continu-
ous wGRS based on MDD GWAS results has been shown to predict de-
pression in independent cohorts, with a pT value of .05 demonstrated to
generate a wGRS that most strongly predicts MDD risk (26). After linkage
disequilibrium pruning, 3010 SNPs were included in the wGRS. The
wGRS was generated for each individual in CARDERA by calculating
the number of nominally associated risk alleles they carried, weighted by
the log odds ratio from the MDD mega-analysis, summed across SNPs.
Statistical Analysis
Associations with MH
Two different modeling approaches were used to evaluate the relationship
between MH, RA severity measures, and genetic risk for depression. The
first approach established whether MH was associated with either RA se-
verity measures or the wGRS for depressive disorder over time. This used
a linear mixed-effects model, which incorporated either MCS or MH mea-
sured at each time point as the response variable regressed on the corre-
sponding predictors (wGRS, DAS28 and its components, HAQ, or pain
VAS) from each time point. Effect size estimates (coefficients) for predictor
variables provided information on the average differences in the MCS or
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MH score for the 2-year period relative to the average predictor variable
score. We have included a level 1 random effect of individual, fitting ran-
dom intercepts for each individual. These models have a level 2 random ef-
fect for time point, modeling deviation from the overall effect of time point
on outcome within each individual as random slopes. We specify this cor-
relation structure using the lme4 package in R (27). The following variables
were tested for their associations withMCS: age, sex, disease duration, and
RF status. Of these, only sex improved the model fit—as determined using
a stepwise selection approach, with the optimal model determined using the
Akaike information criterion—and thus, only this variable was included as
a covariate (Supplementary TablesA.1 and A.2, Supplemental Digital Con-
tent 1, http://links.lww.com/PSYMED/A380). The wGRSwas standardized
to a z score to provide interpretableβ values. Examination of residuals from
a model containing time, sex, and treatment only confirmed a good model
fit (Supplementary Figure A.1, Supplemental Digital Content 1, http://
links.lww.com/PSYMED/A380), and variance inflation factors calculated
for each predictor-ensured multicollinearity between RA outcomes and
DAS28 components were not an issue (Supplementary Table A.3, Supple-
mental Digital Content 1, http://links.lww.com/PSYMED/A380).
The second approach evaluated the direction of associations between
MH andRA severity by testing whetherMH at study baseline was associated
with 2-year changes in RA outcomes over time or vice versa. This used lin-
ear regression models to look at the association between (a) baseline MCS
orMHand2-year changes inRAseveritymeasures and (b) baselineRAseverity
measures and 2-year changes inMH scores. Thesemodels included the base-
line response variable score, treatment, and sex as covariates. Examination
of model residuals confirmed good model fits (Supplementary Figure A.1,
Supplemental Digital Content 1, http://links.lww.com/PSYMED/A380).
Missing Data Imputation
In the original CARDERA-1 trial, missing data at each time point had pre-
viously been imputed using last observation carried forward (LOCF) anal-
ysis for study end points (DAS28, HAQ, and SF-36). LOCF is a commonly
used procedure to address missing data in clinical trials with repeated mea-
sures over multiple time points. For each individual, missing values at a
time point are replaced by the last observed value of that variable
(14,28). In the original CARDERA-2 trial, missing data were not imputed
(15). For consistency in the current analysis, we imputed missing, previ-
ously nonimputed CARDERA-1 data (swollen joint count [SJC], tender
joint count [TJC], ESR, PGA, pain VAS) and missing CARDERA-2 data
using LOCF. The largest amount of missing data was seen for pain VAS
(11% of observations missing across all time points). We repeated our anal-
ysis with nonimputed data only; this excluded a significant impact of the
LOCF assumption (Supplementary Table A.4, Supplemental Digital Con-
tent 1, http://links.lww.com/PSYMED/A380).
Statistical Software
Analyses were performed in the statistical environment R (R Foundation
for Statistical Computing, Vienna, Austria), PRSice (Version 1.2) (29), IM-
PUTE2 (22), and PLINK (Version 1.9) (30).
Ethics, Consent, and Permissions
CARDERA-1 (South ThamesMulticentre Research Ethics Committee (REC)
reference: MREC (1) 99/04) and CARDERA-2 (South East REC reference:
MREC 02/1/089) were ethically approved. Approval was obtained to geno-
type archived DNA (National Research Ethics Service Committee East of
England-EssexREC reference: 11/EE/0544). All patients provided consent.
RESULTS
Patient Baseline Characteristics
Most patients were female (69%, Table 1) and possessed RF
in their serum (67%). Baseline disease activity was high (mean
DAS28 = 5.88), moderate disability (mean HAQ = 1.56), and short
disease duration (mean duration = 3.3 months). Baseline MH was
reduced relative to the general population (meanMCS score = 40.6,
which is 9.4 U lower than the general population mean).
Disease Severity Associations With MH
In a sex- and treatment-adjusted linear mixed-effects model, DAS28
(p < .001), HAQ (p < .001), and pain VAS (p < .001) were signifi-
cantly associated with MCS (Table 2). On average, for 2 years,
MCS scores were 2.22, 6.07, and 0.14 units lower per unit increase
in DAS28, HAQ, and pain VAS scores, respectively. This indicates
that the higher a patient's disease activity, disability, and pain levels,
the worse their MH. In multivariate models, the following three dis-
ease severity measures retained a highly significant association
with MCS (Table 2): HAQ (coefficient = −3.88, p < .001), DAS28
(coefficient = −0.91, p < .001), and pain VAS (coefficient = −0.05,
p < .001). Similar associations were seen with the MH domain.
Major Depressive Disorder Genetic Risk Score
Associations With MH
A significant association was seen between the wGRS for depres-
sion and MCS (p = .013) and MH (p = .041) (Table 2). The asso-
ciation withMCS (p = .033) but not MH (p = .080) was retained in
multivariate models including DAS28, HAQ, and pain VAS as co-
variates. Higher wGRS scores, which indicate a greater genetic
risk for depression, were associated with worse MH (lower MCS
and MH scores) (MCS: coefficient = −1.21; MH: coefficient =
−1.37). Repeating the analysis with a linear mixed-effects model
that incorporated a wGRS-time interaction term provided some
evidence that genetic risk for depression also predicted the rate
at which MH improved across time points, with a significant as-
sociation seen between the wGRS-time term and MH (p = .039,
coefficient = −0.83) but not MCS (p = .330, coefficient = −0.30).
TABLE 1. CARDERAGenetics Cohort Baseline Characteristics
Characteristic
Summary
Statistic
Demographics Female, n (%) 358 (69)
Age, M (SD), y 54.7 (12.6)
RA specific RA duration, M (SD), mo 3.3 (4.9)
RF positive, n (%) 350 (67)
DAS28, M (SD) 5.88 (1.29)
HAQ, M (SD) 1.56 (0.70)
Mental health MCS, M (SD) 40.6 (14.1)
MH, M (SD) 61.0 (18.0)
Treatment Receiving MTX, n (%) 159 (31)
Receiving MTX and CIC, n (%) 108 (21)
Receiving MTX and pred, n (%) 102 (20)
Receiving triple therapy, n (%) 107 (21)
Receiving MTX and anakinra, n (%) 44 (8)
M=mean; SD = standard deviation; RA = rheumatoid arthritis; RF = rheumatoid factor;
DAS28 = disease activity score on a 28-joint count; HAQ = health assessment
questionnaire; MCS = mental component summary score; MH = mental health;
MTX = methotrexate; CIC = ciclosporin; pred = prednisolone; triple therapy =MTX,
CIC, and pred.
Cohort size used in analysis is composed of 520 patients. ADAS28 of 5.88 indicates highly
active disease. AHAQ of 1.56 indicates moderate disability. AnMCS of 40.6 is 9.4 units
lower than that observed in the normal population (which has a mean score of 50.0 units).
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Disease Activity Score on a 28-Joint Count Component
Associations With MH
In a sex- and treatment-adjusted linear mixed-effects model, all four
DAS28 components—SJC, TJC, ESR, and PGA—were associated
with MCS and MH scores when tested individually (Table 2).
Higher scores in each DAS28 component were associated with
lower MCS andMH scores; this indicates that more active disease
is linkedwith poorerMH.On average, for 2 years,MCS scores were
0.32, 0.07, 0.13, and 0.27 units lower per unit increase in SJC,
ESR, PGA, and TJC scores, respectively. In multivariate models
including all four DAS28 components, the TJC failed to retain a
significant association with MCS (p = .461) and MH (p = .519).
Direction of Association Between RAOutcomes andMH
Association Between Baseline Disease Severity and
Changes in MH
The only baseline RA severity measure that had a significant asso-
ciation with 2-year changes in both MCS and MH scores was pain
VAS (Table 3). Higher baseline pain VAS scores (indicating
greater levels of pain) were associated with lesser increases in
MCS and MH scores (indicating lower improvements in MH).
The increase in MCS was 0.07 units less per 1-mm increase in
baseline pain VAS. A significant association between the baseline
TJC and 2-year changes in MH domain scores was also seen
(p = .023), although this variable was not significantly associated
with 2-year changes in MCS scores (p = .122).
Association Between Baseline MH and Changes in
RA Outcomes
Baseline MCS and MH domain scores had significant inverse
associations with 2-year changes in DAS28 (MCS and MH,
p < .001), pain VAS (MCS and MH, p < .001), and HAQ (MCS,
p = .006; MH, p = .008) (Table 3). Lower baseline MCS and MH
scores (indicating poorer MH) were associated with lesser improve-
ments in DAS28, pain VAS, and HAQ scores. The effect sizes
were, however, modest: per 10 unit increase in baseline MCS,
the 2-year reductions in DAS28, HAQ, and pain VAS were 0.20,
0.10, and 3.30 units greater, respectively (Table 3).
Dividing patients into octiles based on their baseline MCS and
plotting the mean disease severity measure in each octile demon-
strated the effect of baseline MCS on RA outcomes (Figure 1).
Trends toward (a) worse disease outcomes at each time point
and (b) lower improvements in disease outcomes for 2 years
across increasing baseline MCS octiles were seen (Figure 1). For
2 years, the mean DAS28, HAQ, and pain VAS scores changed
by −1.14, −0.23, and −8.11 U, respectively, in the lowest MCS
octile (group 1) and −1.94, −0.49, and −18.49 units, respectively,
in the highest MCS octile (group 8).
Examining individual DAS28 components revealed that base-
line MCS andMH scores had significant inverse associations with
2-year changes in the SJC (MCS and MH, p < .001) and PGA
(MCS and MH, p < .001) but not the TJC (MCS, p = .983; MH,
p = .226) and ESR (MCS, p = .973; MH, p = .355) (Table 3). This
differential impact on DAS28 components is shown in Figure 2.
For 2 years, the mean SJC, PGA, TJC, and ESR levels changed
by −0.17, −13.91, −8.02, and −11.98 units, respectively, in the
lowest MCS octile (group 1) and −4.69, −20.46, −5.97, and
−11.03, respectively, in the highest baseline MCS octile (group 8).
DISCUSSION
Our study evaluated the relationship between MH and disease ac-
tivity, disability, pain, and genetic risk for depression for 2 years in
a well-characterized clinical trial cohort of patients with early RA.
It has three key findings. The first, andmost clinically important, is
TABLE 2. Longitudinal Associations Between MH, RA Outcomes, and Depression Genetic Risk Score
MCS MH Domain Score
Sex- and Treatment-Adjusted Model Multivariate Modela Sex- and Treatment-Adjusted Model Multivariate Modela
coefficient (SE) p coefficient (SE) p coefficient (SE) p coefficient (SE) p
RA outcomes
DAS28 −2.22 (0.16) <.001 −0.91 (0.21) <.001 −2.97 (0.21) <.001 −1.37 (0.27) <.001
HAQ −6.07 (0.40) <.001 −3.88 (0.48) <.001 −8.41 (0.53) <.001 −5.75 (0.63) <.001
Pain VAS −0.14 (0.01) <.001 −0.05 (0.01) <.001 −0.17 (0.01) <.001 −0.05 (0.02) .007
Genetic risk
MDD wGRS −1.21 (0.48) .013 −0.92 (0.43) .033 −1.37 (0.67) .041 −1.05 (0.60) .080
DAS28 components
SJC −0.32 (0.04) <.001 −0.12 (0.04) .003 −0.47 (0.05) <.001 −0.25 (0.05) <.001
ESR −0.07 (0.01) <.001 −0.04 (0.01) .003 −0.11 (0.02) <.001 −0.06 (0.02) <.001
PGA −0.13 (0.01) <.001 −0.11 (0.01) <.001 −0.16 (0.01) <.001 −0.11 (0.01) <.001
TJC −0.27 (0.04) <.001 −0.03 (0.04) .461 −0.34 (0.05) <.001 −0.03 (0.05) .519
MCS =mental component summary score;MH=mental health; SE = standard error; RA = rheumatoid arthritis; DAS28 = disease activity score on a 28-joint count; HAQ= health
assessment questionnaire; pain VAS = pain visual analog scale score; MDD wGRS = weighted genetic risk score for major depressive disorder; SJC = swollen joint count; ESR =
erythrocyte sedimentation rate; PGA = patient global assessment of disease activity; TJC = tender joint count.
All linear mixed-effects models include sex, treatment, and time as explanatory variables; multivariate model for DAS28 components also includes SJC, ESR, PGA, and TJC as
explanatory variables.
a Multivariate model for RA outcomes and genetic risk also includes DAS28, HAQ, pain VAS, and MDD wGRS as explanatory variables.
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that lowMHwas associated with poorer disease outcomes. In a re-
peated measures analysis, lower MCS and MH scores had signif-
icant associations with more active disease, increased disability,
and greater pain for 2 years; because MCS and MH scores in-
creased over time, DAS28, HAQ, and pain levels fell. Lower base-
line MCS and MH scores (indicating worse MH) were associated
with a reduced improvement in disease activity and disability, sug-
gesting that depression predicts the degree to which RA improves
over time. The relationship between pain andMH seemed bidirec-
tional, with baseline pain associating with lower improvement in
MCS and MH domain scores and vice versa; this is in keeping
with existing studies of musculoskeletal disorders (7,8).
The second finding was that swollen, but not TJCs, had a sig-
nificant association with reduced MH. In a multivariate model
incorporating all four DAS28 components, the tender joint compo-
nent of the DAS28 (TJC) failed to retain a significant association
with MCS and MH scores. In established RA patients attending
routine clinics, the opposite relationship seems true, with an anal-
ysis of the CORRONA registry reporting that a lifetime depression
history was associated with slower improvements in the TJC but
not the SJC (9). One explanation for the lack of association between
MCS/MH scores and the TJC in CARDERA is that the short
disease duration of patients means the pain pathway sensitiza-
tion characterizing fibromyalgic RA—which could be particularly
TABLE 3. Direction of Associations Between MH and RA Outcomes
MCS MH Domain Score
Model 1: Baseline MCS
Predicting 2-Year Changes
in RA Outcomes
Model 2: Baseline RA
Outcomes Predicting
2-Year Change in MCS
Model 1: Baseline MH
Predicting 2-Year Changes
in RA Outcomes
Model 2: Baseline RA
Outcomes Predicting
2-Year Change in MH
coefficient (SE) p coefficient (SE) p coefficient (SE) p coefficient (SE) p
DAS28 −0.02 (0.01) <.001 −0.31 (0.45) .492 −0.01 (0.00) <.001 −0.83 (0.61) .170
SJC −0.09 (0.02) <.001 0.04 (0.09) .625 −0.07 (0.02) <.001 0.06 (0.12) .577
ESR 0.00 (0.07) .973 0.03 (0.02) .203 −0.05 (0.06) .355 0.01 (0.03) .590
PGA −0.28 (0.08) <.001 −0.03 (0.02) .144 −0.27 (0.06) <.001 −0.05 (0.03) .061
TJC 0.00 (0.02) .983 −0.12 (0.07) .122 −0.02 (0.02) .226 −0.23 (0.10) .023
HAQ −0.01 (0.00) .006 0.50 (0.85) .554 0.00 (0.00) .008 0.19 (1.13) .865
Pain VAS −0.33 (0.08) <.001 −0.07 (0.02) .002 −0.31 (0.06) <.001 −0.08 (0.03) .005
MCS =mental component summary score;MH=mental health; RA = rheumatoid arthritis; SE = standard error; DAS28 = disease activity score on a 28-joint count; SJC = swollen
joint count; ESR = erythrocyte sedimentation rate; PGA = patient global assessment of disease activity; TJC = tender joint count; HAQ = health assessment questionnaire; pain
VAS = pain visual analog scale score.
All linear regression models include sex, treatment, and baseline measure of response variable tested as covariates.
FIGURE 1. Mean DAS28, HAQ, and pain VAS stratified by baseline MCS octile. MCS divided into octiles (8 quantiles); mean scores
with SE bars for octiles 1, 4, 5, and 8 plotted at each time point; to facilitate visual interpretation, octiles 2, 3, 6, and 7 are not plotted,
although the same trends are observed (Supplementary Figure A.2, Supplemental Digital Content 1, http://links.lww.com/PSYMED/
A380). Color image is available only in online version (www.psychosomaticmedicine.org).
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influenced by MH—is yet to occur. An explanation for the associ-
ation observed between MCS/MH scores and the SJC is that over-
lapping proinflammatory cytokines, which are present in high
levels in early active RA, play important roles in mediating both
reduced MH and RA activity. Although this hypothesis is sup-
ported by evidence that administering interleukin 1β and tumor
necrosis factorα induces depressive behavior inmice (31) and that
these cytokines are elevated in the serum of depressed patients
(32,33), it fails to explain why baseline MH scores did not predict
changes in ESR levels. There is an extensive body of literature in-
vestigating the pathophysiology of inflammation-related depres-
sion (34), with one proposed mechanism being the activation of
the enzyme indoleamine 2,3-dioxygenase by inflammatory cyto-
kines, which catabolizes tryptophan leading to a downstream
depletion in serotonin (35)—indeed, inflammation-related depres-
sion seems to be dependent on the activation of indoleamine 2,3-
dioxygenase (36). In light of this, anti-inflammatory medication
has been proposed as a treatment for inflammation-related depres-
sion; however, its efficacy is still contested (37); therefore, further
research is required in other early active RA cohorts to confirm the
generalizability of our results.
Our third finding was that genetic risk for MDD was a signifi-
cant predictor of MH. We tested a wGRS combining 3010 SNPs
of nominal association with MDD in the publicly available Psy-
chiatric Genomics Consortium GWAS for its association with
MH in CARDERA. Although a significant association with lower
MCS and MH scores was observed, the comparatively large stan-
dard error (SE) of the wGRS variable makes any conclusions on its
relative importance challenging. The significant interaction term
for wGRS-time predicting MH, indicating slower improvements
in MH among individuals with high MDD genetic risk, is consis-
tent with previous work indicating that depression genetic risk in-
creases an individual's sensitivity to adverse environmental effects
(38,39). Taken together, these findings support the notion that depres-
sion is a complex disorder with a modest, albeit important, genetic
contribution comprising thousands of alleles of a small effect size.
Our study replicates existing research that depression and pain
have a bidirectional relationship. In CARDERA, baseline MCS
and MH scores predicted 2-year changes in pain VAS and vice
versa. This finding has been documented in psoriatic arthritis; for
example, Husted et al. (7) identified a small bidirectional relation-
ship between MCS and pain in 394 patients followed up for a
mean of 7.5 years. It has also been reported in patients with persis-
tent back, hip, or knee pain (8), back pain (40,41), and pain from a
variety of disorders (42). The complex nature of pain makes it dif-
ficult to discern mechanisms by which this pain-depression bidi-
rectional relationship could occur. Possible mechanisms include
the following: (1) low mood could affect pain through promoting
maladaptive coping strategies, especially catastrophizing (perceiv-
ing a situation to be worse than it is) (43); (2) pain could affect MH
through reducing daily activities (44) and reducing social activities
(45); and (3) imbalances in shared neurotransmitters (serotonin
and norepinephrine) in affective and nociceptive pathways could
contribute to both mood and pain (44). Further research is required
to better characterize the mechanisms underlying this complex
relationship.
Supporting our finding that MH predicts disease outcomes
across time points, other studies have reported a detrimental impact
FIGURE 2. MeanDAS28 components stratified by baselineMCS octile. MCS divided into octiles (8 quantiles); mean scores with SE bars
for octiles 1, 4, 5, and 8 plotted at each time point; to facilitate visual interpretation, octiles 2, 3, 6, and 7 are not plotted, although the same
trends are observed (Supplementary Figure A.3, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A380). Color image is
available only in online version (www.psychosomaticmedicine.org).
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of reduced MH on patients' responsiveness to anti-inflammatory
medication—specifically anti–tumor necrosis factor—as defined
by DAS28 change (46,47). This effect is highly relevant to strati-
fied medicine in RA. Although in CARDERA, the impact of base-
line MCS on improvements in disease outcomes for 2 years was
modest, if considered alongside other poor prognostic markers,
such as anti-citrullinated protein antibody status (48), human leuko-
cyte antigen variants (49), smoking, and sex (50), it could provide
clinically useful prognostic information, guiding decisions on treat-
ment intensity and facilitating a stratified approach to managing
early RA patients.
Our study has several strengths. These include its large size, re-
cruitment from multiple centers spanning two clinical trials, the
measurement of multiple disease outcomes in a highly standard-
ized manner, and the short disease duration of RA (mean =
3.3 months), leaving it well placed to examine the effects of MH
in very early disease. It also has several weaknesses. As a second-
ary post hoc analysis of existing RCTs, it did not test a prespecified
hypothesis according to a predetermined analysis plan. It evalu-
ated a clinical trial cohort of severe RA patients, limiting its gener-
alizability to patients seen in routine clinical practice. In addition,
we only evaluated European ancestry individuals; the relevance
of our findings to other ethnic populations is uncertain.
Current National Institute for Health and Care Excellence
guidelines for RA management recognize the importance of
assessing for comorbid depression, recommending this as part of
an annual review process (51). Our findings strongly support this
recommendation in early RA. One unresolved issue is the impact
of treating depression on the disease course of RA. Although we
did not evaluate the impact of MH therapies on RA outcomes,
there is some evidence that psychological interventions (such as
cognitive behavioral therapy, disclosure therapy, and biofeedback)
are useful adjunctive management tools in RA patients. Two sys-
tematic literature reviews have evaluated the evidence base for
this. Astin et al. (52) reported significant pooled effect sizes for
psychological interventions at reducing postinterventional pain,
disability, and psychological status across 25 trials. Similarly,
Dissanayake and Bertouch (53) found evidence for the efficacy
of disclosure therapy and cognitive behavioral therapy with main-
tenance therapy across four and five studies, respectively. The ev-
idence base is, however, limited with both reviews noting that
available trials had methodological limitations. Further research
is required to better define the impact of specific psychological
interventions at improving disease outcomes in large, well-conducted
clinical trials of RA patients.
CONCLUSIONS
In this cohort of 520 early active RA patients, reduced MH (cap-
tured using the SF-36) was associated with worse disease out-
comes. Lower MCS and MH scores (indicating poorer MH)
were significantly associated with more active disease, increased
disability, and greater pain for 2 years. Worse baseline MH was
associated with lesser improvements in RA outcome measures,
suggesting that depression predicts the rate at which RA improves
over time. A bidirectional relationship was observed between MH
and pain, replicating existing work in musculoskeletal disorders.
Depression genetic risk had a significant, albeit modest, impact on
MH. Our findings support the current National Institute for Health
and Care Excellence RA management guidelines recommending
the annual screening of RA patients for comorbid depression. Fur-
ther research is needed to establish the impact of specific MHman-
agement strategies on improving RA outcomes.
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